ObvioHealth Announces API For More Accurate Adherence and Efficacy Data Collection in Clinical Trials
The new API aims to collect more accurate information by utilizing techniques designed to avoid altering patient behavior.
ObvioHealth announced the launch of an application programming interface (API), which it has designed specifically for clinical trials. The company describes itself as a virtual research organization and it says that the new API will reduce the burden on clinical trial participants while allowing for more data on adherence and efficacy to be captured.
According to the company, the API is better suited for collecting this data compared to traditional questionnaire methods. These questionnaires can potentially influence a patient’s behavior.
The API is available on ObvioHealth’s mobile app.
“Some trial partners will use separate apps to ask many of the same questions that are asked within the DTx— an annoyance for participants and an overly complicated trial design for sponsors. It’s important for sponsors to recognize these study design nuances that can have a dramatic impact on the integrity of study data and participant behavior,” said Ivan Jarry, ObvioHealth’s CEO, in a press release. “ObvioGo’s solution is uniquely positioned to overcome these DTx challenges and facilitate regulatory approvals.”
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
